Your Donation In Action

Your donor dollars are having an impact on research that has the greatest potential to improve prostate cancer prevention, diagnosis and treatment and ensure a better quality of life for survivors.

Projects You Support

CPC-GENE: We have already committed to CPC-GENE, a 5-year, 15-million-dollar project. CPC-GENE aims to identify genetic patterns in men with prostate cancer, information that could be used to better detect tumours, determine tumour aggressiveness and identify the best treatment needed to personalize prostate cancer medicine. This project is supported by Movember.

A Survivorship Action Partnership (ASAP) is a collaborative network focussing on solutions provided by community and clinical organizations that will focus on the physical, mental and spiritual well-being of patients and their loved ones throughout the prostate cancer journey. This is a 10-million dollar investment over 3 years provided by Movember.

Clinician Scientist Awards: These awards provide salary and research support for outstanding clinician scientists initiating a career as independent investigators/junior faculty in prostate cancer research. Via Movember, your dollars supported 5 of these awards in 2012. For example, your funds enabled Dr. Peter Black at UBC to study a microfluidic device to detect cancer cells not picked up by standard methods. Identifying these cells may act as a biomarker of the patient’s disease status, help researchers learn more about how cancer spreads, and may reveal new targets for emerging treatments.

Pilot Grants: Funded by Movember, the Pilot Grant program supports innovative research ideas that are at a very early stage with separate categories for new and established investigators. In 2012, your donor dollars supported 36 pilot grants. One innovative example is Jewish General Hospital (Montreal) Dr. Trifiro’s research, which looks at a “Trojan horse” approach used to target and kill prostate cancer cells using ultrasound.

PC- STAR: This project, funded by Safeway’s generous support of our Father’s Day Walk/Run, is conducted by researchers at the Prostate Cancer Centre in Vancouver and is focused on developing new treatments for prostate cancer when the tumour has spread and become hormone independent.

BRCA 1/2: This national study looks at men who carry BRCA 1 and BRCA 2 genetic mutations, comparing those who have a family history of prostate cancer with patients who do not. The study is being led by a group of researchers in Toronto but involves collaborations with other researchers across Canada and is funded via PCC.

More Information:
Financial Information
Ethics & Accountability
Privacy Policy
 


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
New test developed to detect men at high risk of prostate cancer recurrence

Vienna, Austria: A new genetic “signature” to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). More

CanCertainty for All: Cancer’s Not Fair, But Accessing Treatment Should Be

Toronto, ON – March 10, 2014 – There is no disputing a cancer diagnosis is among the worst news a person or their family could receive. More

$1.8 Million awarded to Movember Rising Stars Supporting Innovators in Prostate Cancer Research

Toronto, ON – February 12, 2014 – Prostate Cancer Canada (PCC) is proud to announce the recipients of its 2014 Movember Rising Star awards in prostate cancer research. More

Support for Those Affected by Prostate Cancer

Toronto, ON - January 28, 2014 – We are pleased to announce a partnership between Prostate Cancer Canada and the Canadian Cancer Society in launching the Prostate Cancer Information Service (PCIS), which provides support to anyone affected by prostate cancer. More


Click here for news archive